ceftobiprole (Zeftera/Zevtera)
Jump to navigation
Jump to search
Introduction
FDA-approval pending, March 2010
Indications
- treatment of complicated skin & skin-structure infections, including diabetic foot infections
- ventilator-associated pneumonia[5]
Dosage
500 mg IV every 12 hours Antibiotic sensitivity:
- methicillin-resistant Staphylococcus aureus (MRSA)[4]
- penicillin-resistant Streptococcus pneumonia
- Gram-negative bacteria, including Pseudomonas
Adverse effects
- nausea (14%)
- taste disturbance (8%)
More general terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- ↑ Wikipedia: Ceftobiprole http://en.wikipedia.org/wiki/Ceftobiprole
- ↑ Noel GJ et al Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria Antimicrobial Agents and Chemotherapy, 2008, 52:37-44 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/17954698 <Internet> http://aac.asm.org/cgi/content/abstract/52/1/37?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=bacteria&searchid=1&FIRSTINDEX=3030&resourcetype=HWFIG
- ↑ 4.0 4.1 Vidaillac C, Rybak MJ. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Pharmacotherapy. 2009 May;29(5):511-25. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19397461
- ↑ 5.0 5.1 Rapid Review Quiz: Hospital-Acquired Pneumonia Medscape. Sept 15, 2022 https://reference.medscape.com/viewarticle/980567